Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors
Moore, M., Hirte, H. W., Siu, L., Oza, A., Hotte, S. J., Petrenciuc, O., Cihon, F., Lathia, C., Schwartz, B.
Published in Annals of oncology (01.10.2005)
Published in Annals of oncology (01.10.2005)
Get full text
Journal Article
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
Sahebjam, S, Bedard, P L, Castonguay, V, Chen, Z, Reedijk, M, Liu, G, Cohen, B, Zhang, W-J, Clarke, B, Zhang, T, Kamel-Reid, S, Chen, H, Ivy, S P, Razak, A R A, Oza, A M, Chen, E X, Hirte, H W, McGarrity, A, Wang, L, Siu, L L, Hotte, S J
Published in British journal of cancer (20.08.2013)
Published in British journal of cancer (20.08.2013)
Get full text
Journal Article
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
Razak, A R A, Hotte, S J, Siu, L L, Chen, E X, Hirte, H W, Powers, J, Walsh, W, Stayner, L-A, Laughlin, A, Novotny-Diermayr, V, Zhu, J, Eisenhauer, E A
Published in British journal of cancer (01.03.2011)
Published in British journal of cancer (01.03.2011)
Get full text
Journal Article
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study
Hotte, S.J., Oza, A., Winquist, E.W., Moore, M., Chen, E.X., Brown, S., Pond, G.R., Dancey, J.E., Hirte, H.W.
Published in Annals of oncology (01.02.2006)
Published in Annals of oncology (01.02.2006)
Get full text
Journal Article
Telomerase Activity in Human Ovarian Carcinoma
COUNTER, C. M, HIRTE, H. W, BACCHETTI, S, HARLEY, C. B
Published in Proceedings of the National Academy of Sciences - PNAS (12.04.1994)
Published in Proceedings of the National Academy of Sciences - PNAS (12.04.1994)
Get full text
Journal Article
Telomerase activity associated with acquisition of malignancy in human colorectal cancer
CHADENEAU, C, HAY, K, HIRTE, H. W, GALLINGER, S, BACCHETTI, S
Published in Cancer research (Chicago, Ill.) (15.06.1995)
Get full text
Published in Cancer research (Chicago, Ill.) (15.06.1995)
Journal Article
Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review
Hirte, H W, Strychowsky, J E, Oliver, T, Fung-Kee-Fung, M, Elit, L, Oza, A M
Published in International journal of gynecological cancer (01.11.2007)
Published in International journal of gynecological cancer (01.11.2007)
Get full text
Journal Article
A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers
MacKenzie, M. J., Hirte, H. W., Siu, L. L., Gelmon, K., Ptaszynski, M., Fisher, B., Eisenhauer, E.
Published in Annals of oncology (01.04.2004)
Published in Annals of oncology (01.04.2004)
Get full text
Journal Article
Optimal chemotherapy treatment for women with recurrent ovarian cancer
Fung-Kee-Fung, M, Oliver, T, Elit, L, Oza, A, Hirte, H W, Bryson, P
Published in Current oncology (Toronto) (01.10.2007)
Published in Current oncology (Toronto) (01.10.2007)
Get full text
Journal Article
Telomerase, cell immortality, and cancer
Harley, C B, Kim, N W, Prowse, K R, Weinrich, S L, Hirsch, K S, West, M D, Bacchetti, S, Hirte, H W, Counter, C M, Greider, C W
Published in Cold Spring Harbor Symposia on Quantitative Biology (1994)
Published in Cold Spring Harbor Symposia on Quantitative Biology (1994)
Get more information
Journal Article
A Randomized Trial of Paracentesis plus Intraperitoneal Tumor Necrosis Factor-α versus Paracentesis Alone in Patients with Symptomatic Ascites from Recurrent Ovarian Carcinoma
Hirte, H.W., Miller, D., Tonkin, K., Findlay, B., Capstick, V., Murphy, J., Buckman, R., Carmichael, J., Levine, M., Hill, W.
Published in Gynecologic oncology (01.01.1997)
Published in Gynecologic oncology (01.01.1997)
Get full text
Journal Article
Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum--a systematic review of the evidence from randomized trials
Fung, M Fung Kee, Johnston, M E, Eisenhauer, E A, Elit, L, Hirte, H W, Rosen, B
Published in European journal of gynaecological oncology (2002)
Get more information
Published in European journal of gynaecological oncology (2002)
Journal Article
Induction of hTERT Expression and Telomerase Activity by Estrogens in Human Ovary Epithelium Cells
Misiti, Silvia, Nanni, Simona, Fontemaggi, Giulia, Cong, Yu-Sheng, Wen, Jianping, Hirte, Hal W., Piaggio, Giulia, Sacchi, Ada, Pontecorvi, Alfredo, Bacchetti, Silvia, Farsetti, Antonella
Published in Molecular and Cellular Biology (01.06.2000)
Published in Molecular and Cellular Biology (01.06.2000)
Get full text
Journal Article
A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial
Hirte, H. W., Vidal, L., Fleming, G. F., Sugimoto, A. K., Morgan, R. J., Biagi, J. J., Wang, L., McGill, S., Ivy, S. P., Oza, A. M.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article
A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma
Hirte, H.W., Clark, D.A., Mazurka, J., O'Connell, G., Rusthoven, J.
Published in Gynecologic oncology (01.03.1992)
Published in Gynecologic oncology (01.03.1992)
Get full text
Journal Article